BIOMAT Database Logo BIOMAT Database Logo

A challenging case of Kikuchi-Fujimoto disease with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis in a young man. 2021

Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Department of Dermatology, All India Institute of Medical Sciences, Patna, Bihar.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006886 Hydroxychloroquine A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) Hydroxychlorochin,Oxychlorochin,Oxychloroquine,Hydroxychloroquine Sulfate,Hydroxychloroquine Sulfate (1:1) Salt,Plaquenil
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D051359 Lymphohistiocytosis, Hemophagocytic A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive. Familial Hemophagocytic Lymphocytosis,Hemophagocytic Lymphohistiocytosis, Familial,Hemophagocytic Syndrome, Infection-Associated,Hemophagocytic Syndrome, Reactive,Hemophagocytic Syndromes,Reactive Hemophagocytic Syndrome,Erythrophagocytic Lymphohistiocytosis, Familial,Familial Erythrophagocytic Lymphohistiocytosis,Familial Hemophagocytic Histiocytosis,Familial Hemophagocytic Lymphohistiocytosis,Familial Hemophagocytic Reticulosis,Familial Histiocytic Reticulosis,Hemophagocytic Lymphohistiocytosis Familial -1,Hemophagocytic Lymphohistiocytosis, Familial, 1,Hemophagocytic Reticulosis, Familial,Hemophagocytic Syndrome,Primary Hemophagocytic Hymphohistiocytosis,Primary Hemophagocytic Lymphohistiocytosis,Reticulosis, Familial Histiocytic,Erythrophagocytic Lymphohistiocytoses, Familial,Familial Erythrophagocytic Lymphohistiocytoses,Familial Hemophagocytic Histiocytoses,Familial Hemophagocytic Lymphocytoses,Familial Hemophagocytic Lymphohistiocytoses,Familial Hemophagocytic Reticuloses,Familial Histiocytic Reticuloses,Hemophagocytic Histiocytoses, Familial,Hemophagocytic Histiocytosis, Familial,Hemophagocytic Hymphohistiocytoses, Primary,Hemophagocytic Hymphohistiocytosis, Primary,Hemophagocytic Lymphocytoses, Familial,Hemophagocytic Lymphocytosis, Familial,Hemophagocytic Lymphohistiocytoses,Hemophagocytic Lymphohistiocytoses, Familial,Hemophagocytic Lymphohistiocytoses, Primary,Hemophagocytic Lymphohistiocytosis,Hemophagocytic Lymphohistiocytosis Familial 1,Hemophagocytic Lymphohistiocytosis, Primary,Hemophagocytic Reticuloses, Familial,Hemophagocytic Syndrome, Infection Associated,Histiocytic Reticuloses, Familial,Histiocytic Reticulosis, Familial,Histiocytoses, Familial Hemophagocytic,Histiocytosis, Familial Hemophagocytic,Hymphohistiocytoses, Primary Hemophagocytic,Hymphohistiocytosis, Primary Hemophagocytic,Infection-Associated Hemophagocytic Syndrome,Lymphocytoses, Familial Hemophagocytic,Lymphocytosis, Familial Hemophagocytic,Lymphohistiocytoses, Familial Erythrophagocytic,Lymphohistiocytoses, Familial Hemophagocytic,Lymphohistiocytoses, Hemophagocytic,Lymphohistiocytoses, Primary Hemophagocytic,Lymphohistiocytosis, Familial Erythrophagocytic,Lymphohistiocytosis, Familial Hemophagocytic,Lymphohistiocytosis, Primary Hemophagocytic,Primary Hemophagocytic Hymphohistiocytoses,Primary Hemophagocytic Lymphohistiocytoses,Reticuloses, Familial Hemophagocytic,Reticuloses, Familial Histiocytic,Reticulosis, Familial Hemophagocytic
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents
D020042 Histiocytic Necrotizing Lymphadenitis Development of lesions in the lymph node characterized by infiltration of the cortex or paracortex by large collections of proliferating histiocytes and complete or, more often, incomplete necrosis of lymphoid tissue. Kikuchi Disease,Lymphadenitis, Histiocytic Necrotizing,Histiocytic Necrotising Lymphadenitis,Kikuchi Necrotizing Lymphadenitis,Kikuchi's Disease,Kikuchi-Fujimoto Disease,Kikuchi-Fujimoto's Disease,Nosocomial Kikuchi's Disease,Disease, Kikuchi,Disease, Kikuchi's,Disease, Kikuchi-Fujimoto,Disease, Kikuchi-Fujimoto's,Histiocytic Necrotising Lymphadenitides,Kikuchi Fujimoto Disease,Kikuchi Fujimoto's Disease,Kikuchi's Disease, Nosocomial,Kikuchi-Fujimotos Disease,Kikuchis Disease,Lymphadenitides, Histiocytic Necrotising,Lymphadenitis, Histiocytic Necrotising,Lymphadenitis, Kikuchi Necrotizing,Necrotising Lymphadenitides, Histiocytic,Necrotising Lymphadenitis, Histiocytic,Necrotizing Lymphadenitis, Histiocytic,Necrotizing Lymphadenitis, Kikuchi,Nosocomial Kikuchi Disease,Nosocomial Kikuchis Disease

Related Publications

Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto disease associated with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report.
June 2019, Journal of medical case reports,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto disease complicated with hemophagocytic lymphohistiocytosis.
June 2023, Pediatric blood & cancer,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto Disease Complicated with Reactive Hemophagocytic Lymphohistiocytosis.
October 2016, Acta medica Okayama,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Hemophagocytic lymphohistiocytosis with recurrent Kikuchi-Fujimoto disease.
July 2021, Yeungnam University journal of medicine,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Relapsing Kikuchi-Fujimoto Disease With Hemophagocytic Lymphohistiocytosis.
December 2022, Cureus,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto disease associated with systemic lupus erythematosus.
August 2011, NDT plus,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto disease associated with systemic lupus erythematosus.
December 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto Disease Heralding Systemic Lupus Erythematosus.
December 2020, The Journal of the American Osteopathic Association,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Kikuchi-Fujimoto disease and systemic lupus erythematosus.
January 2016, International medical case reports journal,
Swetalina Pradhan, and Chandra Sekhar Sirka, and Gaurav Dash, and Kananbala Sahu, and Arpita Nibedita Rout
Macular capillary recovery in systemic lupus erythematosus complicated by Kikuchi-Fujimoto disease.
August 2018, International ophthalmology,
Copied contents to your clipboard!